Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
- Response deadline
- Oct 23, 2026 Due in 30 days
- Date posted
- Sep 23, 2026
- Source
- Open notice
Description
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.
Classifications
Documents (14)
- Attachment I1 - Technology Readiness Level (TRL) for drug and biologics (REFERENCE ONLY).pdf.pdf241 KBNot yet available
- Attachment I2-Technology Readiness Level (TRL) for diagnostics and devices (REFERENCE ONLY).pdf.pdf269 KBNot yet available
- HT9427-26-R-E020-RPP for BWI-PT-Barrier (pOTA).pdf.pdf379 KBNot yet available
- Attachment D2 - FDA Form 1571 Instructions (REFERENCE ONLY).pdf.pdf342 KBNot yet available
- Attachment G2 - Firm Fixed Price Sheet Template.xlsx.xlsx143 KBNot yet available
- Attachment J - Offeror question form.xlsx.xlsx11 KBNot yet available
- Attachment D1 - FDA Form 1571.pdf.pdf388 KBNot yet available
- Attachment B - Contract Data Requirements List (CDRL).pdf.pdf54 KBNot yet available
- Attachment A - Statement of Objectives (SOO).pdf.pdf189 KBNot yet available
- Attachment F - Warranties and Representatives.docx.docx30 KBNot yet available
- Attachment C - Data Item Description (DID) DI-TCSP-82040 (REFERENCE ONLY).pdf.pdf353 KBNot yet available
- Attachment E - Draft Agreement Terms and Conditions.pdf.pdf781 KBNot yet available
- Attachment G1 - Cost Sheet Template.xlsx.xlsx158 KBNot yet available
- Attachment H - Statement of Work Template (see Section 11).docx.docx61 KBNot yet available
Contacts
Similar contracts
- ARGOS Camera DevelopmentMarylandDue Sep 28, 2026
- Rendezvous, Proximity Operations (RPO) Threat Response (RTR) VICTUS Responsive Launch Space Vehicle (SV)CaliforniaDue Oct 19, 2026
- Synthetic Training Environment (STE) Virtual Software (VSW)FloridaDue Sep 29, 2026
- Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partnersMarylandDue Oct 18, 2028
- Special Supplemental Nutrition Program for Women Infants and ChildrenDistrict of ColumbiaDue Sep 29, 2026
- Performance Enhanced Real-time Ground Environment (PEREGRINE) SentryDue Oct 23, 2026